首页> 外文期刊>Biochemical and Biophysical Research Communications >miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2
【24h】

miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2

机译:miR-139-5p通过靶向ZEB1和ZEB2抑制肝癌细胞的上皮-间质转化,迁移和侵袭

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths worldwide. miRNAs have been suggested to have important roles in HCC development. The purpose of this study was to determine the role of miR-139-5p in regulation of epithelial mesenchymal transition (EMT) and metastasis of HCC cells. Expression levels of miR-139-5p in 49 HCC specimens with adjacent tissues and five HCC cell lines were assessed by quantitative RT-PCR. We found that miR-139-5p was down-regulated in 89.7% of the HCC tissue samples and all of the HCC cell lines. In addition, luciferase reporter assays validated direct binding of miR-139-5p to the 3' untranslated region of zinc finger E-box binding homeobox 1 (ZEB1) and ZEB2. Ectopic expression of miR-139-5p suppressed and miR-139-in promoted EMT, migration, and invasion in Hep3B and SMMC7721 cells. Furthermore, over-expression of ZEB1 and ZEB2 ablated the inhibitory effects of miR-139-5p on migration and invasion in HCC cells. Our study indicates that miR-139-5p functions as a suppressor of HCC EMT and metastasis by targeting ZEB1 and ZEB2, and it may be a therapeutic target for metastatic HCC. (C) 2015 Elsevier Inc. All rights reserved.
机译:肝细胞癌(HCC)是全球第三大最常见的癌症死亡原因。已经提出miRNA在HCC发展中具有重要作用。这项研究的目的是确定miR-139-5p在调控上皮间质转化(EMT)和HCC细胞转移中的作用。通过定量RT-PCR评估了49例具有邻近组织的HCC标本和5个HCC细胞系中miR-139-5p的表达水平。我们发现在89.7%的HCC组织样品和所有HCC细胞系中miR-139-5p均下调。此外,萤光素酶报告基因检测验证了miR-139-5p与锌指E-box结合同源异型盒1(ZEB1)和ZEB2的3'非翻译区的直接结合。在Hep3B和SMMC7721细胞中,miR-139-5p的异位表达受到抑制,miR-139-in促进了EMT,迁移和侵袭。此外,ZEB1和ZEB2的过表达消除了miR-139-5p对HCC细胞迁移和侵袭的抑制作用。我们的研究表明,miR-139-5p通过靶向ZEB1和ZEB2充当HCC EMT和转移的抑制剂,并且它可能是转移性HCC的治疗靶标。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号